Paper40713639
Multi-omics based and AI-driven drug repositioning for epigenetic therapy in female malignancies.
Salvati A and 14 others. J Transl Med, 2025. Cited by 25 papers, by iCite.
Cite this record
ConductScience Library. Multi-omics based and AI-driven drug repositioning for epigenetic therapy in female malignancies. Papers, record 40713639. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40713639
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Multi-omics based and AI-driven drug repositioning for epigenetic therapy in female malignancies.
- PubMed
Topics8
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Drug Repositioning | Major topic |
| Artificial Intelligence | Major topic |
| Epigenesis, Genetic | Major topic |
| Neoplasms | Major topic |
| Humans | |
| Female | |
| Breast Neoplasms | |
| Multiomics |
Source PubMed
Grants3
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| IG-23068 | Fondazione AIRC per la ricerca sul cancro ETS | PubMed | ||
| 202282CMEA | Ministero dell'Università e della Ricerca | PubMed | ||
| 2022A7HJEM | Ministero dell'Università e della Ricerca | PubMed |
Source PubMed
References227
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 15988529 | Global histone modification patterns predict risk of prostate cancer recurrence. | Nature | 2005 | https://conductscience.org/library/papers/15988529 | PubMed |
| 2 | 21576221 | Tracking epigenetic histone modifications in single cells using Fab-based live endogenous modification labeling. | Nucleic Acids Res | 2011 | https://conductscience.org/library/papers/21576221 | PubMed |
| 3 | 24994966 | Histone H3 lysine 27 acetylation is altered in colon cancer. | Clin Proteomics | 2014 | https://conductscience.org/library/papers/24994966 | PubMed |
| 4 | 18347167 | Class I histone deacetylase expression has independent prognostic impact in human colorectal cancer: specific role of class I histone deacetylases in vitro and in vivo. | Clin Cancer Res | 2008 | https://conductscience.org/library/papers/18347167 | PubMed |
| 5 | 21423274 | Readers of histone modifications. | Cell Res | 2011 | https://conductscience.org/library/papers/21423274 | PubMed |
| 6 | 35427480 | Beyond the marks: reader-effectors as drivers of epigenetics and chromatin engineering. | Trends Biochem Sci | 2022 | https://conductscience.org/library/papers/35427480 | PubMed |
| 7 | 29651053 | Targeted in situ genome-wide profiling with high efficiency for low cell numbers. | Nat Protoc | 2018 | https://conductscience.org/library/papers/29651053 | PubMed |
| 8 | 28689145 | Allosteric regulation of epigenetic modifying enzymes. | Curr Opin Chem Biol | 2017 | https://conductscience.org/library/papers/28689145 | PubMed |
| 9 | 30364956 | HMDD v3.0: a database for experimentally supported human microRNA-disease associations. | Nucleic Acids Res | 2019 | https://conductscience.org/library/papers/30364956 | PubMed |
| 10 | 34786648 | The Clinical Value of Decitabine Monotherapy in Patients with Acute Myeloid Leukemia. | Adv Ther | 2022 | https://conductscience.org/library/papers/34786648 | PubMed |
| 11 | 30478442 | A primer on deep learning in genomics. | Nat Genet | 2019 | https://conductscience.org/library/papers/30478442 | PubMed |
| 12 | 33879235 | Advances in epigenetic therapeutics with focus on solid tumors. | Clin Epigenetics | 2021 | https://conductscience.org/library/papers/33879235 | PubMed |
| 13 | 26865995 | HDAC and HDAC Inhibitor: From Cancer to Cardiovascular Diseases. | Chonnam Med J | 2016 | https://conductscience.org/library/papers/26865995 | PubMed |
| 14 | 18004079 | Clinical significance of histone deacetylase 1 expression in patients with hepatocellular carcinoma. | Oncology | 2007 | https://conductscience.org/library/papers/18004079 | PubMed |
| 15 | 29264942 | MethSurv: a web tool to perform multivariable survival analysis using DNA methylation data. | Epigenomics | 2018 | https://conductscience.org/library/papers/29264942 | PubMed |
| 16 | 32079180 | Decitabine Augments Chemotherapy-Induced PD-L1 Upregulation for PD-L1 Blockade in Colorectal Cancer. | Cancers (Basel) | 2020 | https://conductscience.org/library/papers/32079180 | PubMed |
| 17 | 21559012 | A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer. | Br J Cancer | 2011 | https://conductscience.org/library/papers/21559012 | PubMed |
| 18 | 21889194 | BET bromodomain inhibition as a therapeutic strategy to target c-Myc. | Cell | 2011 | https://conductscience.org/library/papers/21889194 | PubMed |
| 19 | 38640748 | A phase I study to evaluate the safety, pharmacokinetics, and pharmacodynamics of PF-06939999 (PRMT5 inhibitor) in patients with selected advanced or metastatic tumors with high incidence of splicing factor gene mutations. | ESMO Open | 2024 | https://conductscience.org/library/papers/38640748 | PubMed |
| 20 | 39138146 | Therapeutic advances of targeting receptor tyrosine kinases in cancer. | Signal Transduct Target Ther | 2024 | https://conductscience.org/library/papers/39138146 | PubMed |
Cited by20
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 25 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42882485 | The Crosstalk Between Metabolic Reprogramming and Histone Methylation in Tumor Immunity and Immunotherapy. | Cells | 2026 | https://conductscience.org/library/papers/42882485 | PubMed |
| 42840418 | The impact of epigenetics on tumor metabolism: Friend or foe in drug response? | Front Epigenet Epigenom | 2026 | https://conductscience.org/library/papers/42840418 | PubMed |
| 42610144 | AI-driven CRISPR strategies in breast cancer: Organoid modeling, adaptive editing, and precision delivery. | Iran J Basic Med Sci | 2026 | https://conductscience.org/library/papers/42610144 | PubMed |
| 42405329 | Tumor suppressor network dysregulation in neuroblastoma: molecular mechanisms and precision therapeutic opportunities. | Front Cell Dev Biol | 2026 | https://conductscience.org/library/papers/42405329 | PubMed |
| 42347061 | From Laboratory to Patient Access: A Scoping Review of the Multi-Dimensional Challenges in Drug Repurposing. | Pharmacy (Basel) | 2026 | https://conductscience.org/library/papers/42347061 | PubMed |
| 42346864 | c-Myc-Induced Therapy Resistance in Leukemia: Mechanisms and Emerging Therapeutic Opportunities. | Med Sci (Basel) | 2026 | https://conductscience.org/library/papers/42346864 | PubMed |
| 42130861 | PTM encoding: decoding the mechanisms of exercise-induced metabolic memory through spatiotemporal modification networks. | Front Sports Act Living | 2026 | https://conductscience.org/library/papers/42130861 | PubMed |
| 42058150 | Bridging science and hope: the evolving story of gene therapy for neuromuscular diseases. | Front Cell Dev Biol | 2026 | https://conductscience.org/library/papers/42058150 | PubMed |
| 42052446 | Multimodal artificial intelligence in urologic precision oncology: from algorithm to translational medicine (a systemized narrative review). | Front Oncol | 2026 | https://conductscience.org/library/papers/42052446 | PubMed |
| 41971420 | Breast cancer pathogenesis, diagnosis and treatment: a comprehensive review. | Front Oncol | 2026 | https://conductscience.org/library/papers/41971420 | PubMed |
| 41618311 | Identification of LncRNAs scaffolding a chromatin-associated gene regulatory complex in breast cancer cells comprising ERα, DOT1L and menin. | Cell Commun Signal | 2026 | https://conductscience.org/library/papers/41618311 | PubMed |
| 41523619 | Mapping the Landscape of Anti-Breast Cancer Drug Discovery in Saudi Arabia: A Bibliometric Analysis (2019-2023). | Scientifica (Cairo) | 2025 | https://conductscience.org/library/papers/41523619 | PubMed |
| 41471222 | From Methylomes to CRISPR Epigenetic Editing: New Paths in Antibiotic Resistance. | Pathogens | 2025 | https://conductscience.org/library/papers/41471222 | PubMed |
| 41439866 | Integrating New Approach Methodologies (NAMs) into Preclinical Regulatory Evaluation of Oncology Drugs. | Biomimetics (Basel) | 2025 | https://conductscience.org/library/papers/41439866 | PubMed |
| 41329030 | Epigenetic Regulation of Autophagy in Breast Cancer: Implications for Biomarker Discovery and Personalized Therapy. | Cancer Rep (Hoboken) | 2025 | https://conductscience.org/library/papers/41329030 | PubMed |
| 41311372 | Emerging hallmarks and the rise of complexities and heterogeneity of tumor. | Biochem Biophys Rep | 2025 | https://conductscience.org/library/papers/41311372 | PubMed |
| 41266662 | AI-driven multi-omics integration in precision oncology: bridging the data deluge to clinical decisions. | Clin Exp Med | 2025 | https://conductscience.org/library/papers/41266662 | PubMed |
| 41209039 | Computational strategies in tumor phylogenetics: evaluating multimodal integration and methodological trade-offs across study designs. | Bioinform Adv | 2025 | https://conductscience.org/library/papers/41209039 | PubMed |
| 41150690 | Regulatory challenges and opportunities in cell-based therapies: overcoming barriers to advancement and patient care. | Regen Med | 2025 | https://conductscience.org/library/papers/41150690 | PubMed |
| 41057770 | MMP11 predicts colorectal cancer outcomes and its inhibitor RXP03 exerts anti-tumor effects via apoptosis activation. | BMC Gastroenterol | 2025 | https://conductscience.org/library/papers/41057770 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/40713639
GET https://conductscience.org/api/papers/v1/40713639/references?page=2